MicroTransponder’s Vivistim system continues to demonstrate clinical value in stroke recovery, with new one-year follow-up data revealing sustained improvements in motor function and quality of life.
Vivistim, an FDA-approved implantable neurostimulator, uses vagus nerve stimulation (VNS) paired with rehabilitation therapy. In a study of 74 chronic stroke survivors, 66.2% showed a positive response to the therapy. Participants saw an average improvement of 5.23 points on the Fugl-Meyer Assessment–Upper Extremity and 0.50 on the Wolf Motor Function Test.
“These long-term outcomes are particularly notable because sustained, comprehensive benefits are rarely shown in chronic stroke recovery,” said study lead Dr. Teresa Jacobson Kimberley.
The company also cited earlier 2025 data showing a 9.53-point improvement in a separate group of post-acute stroke patients. MicroTransponder raised $65 million in Series F funding in March to expand partnerships with leading stroke centers.
Follow MEDWIRE.AI for neurostimulation innovation in stroke recovery.
